Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
Cancer Treatment and Research Communications|January 27, 2020
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testingPanagiotis J Vlachostergios, Bishoy M Faltas, Maria I Carlo, et al.Postgraduate Medical Journal|March 31, 2023
The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!Katherine A A ClarkHuman Genomics|March 25, 2024
Clinical spectrum of Transthyretin amyloidogenic mutations among diverse population originsAntonella De Lillo, Gita A Pathak, Aislinn Low, et al.Pediatric Blood & Cancer|July 21, 2017
Routine surveillance imaging after end of therapy for pediatric extracranial tumors: A retrospective analysisFarah Lakkis, Sarah Abou Alaiwi, Lena Naffaa, et al.The American Journal of Managed Care|September 7, 2023
Defining a path toward improved heart failure careNihar R Desai, Katherine A A ClarkUrologic Oncology|January 13, 2022
Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groupsChethan Ramamurthy, Amin H Nassar, Sarah Abou Alaiwi, et al.Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.Clinical Genitourinary Cancer|May 20, 2021
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial CarcinomaRohit K Jain, William Paul Skelton Iv, Gregory Russell Pond, et al.Journal for Immunotherapy of Cancer|April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsPier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.Molecular Cancer Therapeutics|June 10, 2021
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting AgentEddy S Yang, Amin H Nassar, Elio Adib, et al.Pageof 6